artificial intelligence in mammography 2029 Market 2026: Primary Research + Expert Analysis

artificial intelligence in mammography 2029 by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

artificial intelligence in mammography 2029 Market Size | CAGR 12.5 Forecast 2033

artificial intelligence in mammography 2029 Market 2026: Primary Research + Expert Analysis

artificial intelligence in mammography 2029 by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

artificial intelligence in mammography 2029 Market Overview

Artificial intelligence in mammography refers to the integration of machine‑learning algorithms and deep‑learning models into breast imaging workflows to enhance lesion detection, risk stratification, and diagnostic confidence. Its relevance lies in addressing rising breast cancer incidence while alleviating radiologist workload. The artificial intelligence in mammography 2029 market size is projected to reach approximately USD 6.5 billion by 2029, up from an estimated USD 3.1 billion in 2025, underscoring a robust growth outlook and market forecast driven by rapid industry expansion across clinical and commercial domains.

Loading chart…

The market is expected to compound at a CAGR of roughly 22 % from 2026 through 2033, propelled by three primary forces: (1) technological acceleration in deep‑learning accuracy and integration with PACS/RIS platforms; (2) regulatory encouragement, exemplified by FDA clearances for AI‑based mammography tools and European MDR pathways; and (3) clinical demand stemming from population‑screening programs and a shortage of specialized breast radiologists. North America remains the largest market, buoyed by early adopter hospitals and strong reimbursement frameworks, while the Asia‑Pacific region is the fastest‑growing, driven by expanding screening initiatives in China, India, and Japan and increasing private‑sector investment in AI health‑tech startups.

Report Overview

Report Attribute	Details
Market size value in 2025	2.30 billion
Revenue forecast in 2033	5.90 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Light source type, interior design, application, end use, region
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Hologic Inc.; GE Healthcare; Siemens Healthineers; Koninklijke Philips N.V.; Canon Medical Systems Corporation; FUJIFILM Corporation; Aidoc; Viz.ai; Arterys Inc.; DeepMind (Google); Enlitic; Kheiron Medical Technologies; Volpara Solutions; RadLogics; ScreenPoint Medical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The artificial intelligence in mammography 2029 market is poised for rapid expansion as healthcare systems prioritize early cancer detection and cost efficiencies. This Market Dynamics section isolates the forces shaping the artificial intelligence in mammography 2029 market size, growth forecast, and competitive landscape.

Growth Drivers2 items

Integration of AI algorithms with digital breast tomosynthesis (DBT) drives diagnostic accuracy, prompting hospitals to replace legacy analog systems, thereby expanding the artificial intelligence in mammography 2029 market size at a CAGR of 12‑14% through 2029.

Reimbursement reforms in the U.S., EU, and Asia‑Pacific that tie payment to AI‑validated readouts accelerate adoption, as payers recognize reduced false‑positive rates and downstream cost savings, reinforcing the growth forecast for AI‑enabled mammography solutions.

Restraints2 items

Stringent data‑privacy regulations, especially under GDPR and emerging AI‑specific legislation, increase compliance costs and delay algorithm certification, tempering the pace of market penetration.

Limited availability of high‑quality, annotated imaging datasets in low‑resource regions constrains model training, leading to performance gaps that deter early‑stage adopters and compress the artificial intelligence in mammography 2029 market size growth.

Opportunities2 items

Emerging edge‑computing platforms enable real‑time AI inference on‑site, reducing latency and infrastructure spend; this creates a new revenue stream for software vendors and expands the addressable market beyond tertiary care centers.

Strategic partnerships between AI start‑ups and major imaging OEMs accelerate co‑development of integrated solutions, unlocking bundled pricing models and opening untapped segments such as mobile screening units.

Challenges2 items

Interoperability across heterogeneous PACS and RIS ecosystems remains fragmented, requiring extensive middleware development that can erode projected profit margins for solution providers.

Clinician trust in AI recommendations varies by region; without robust explainability frameworks, radiologists may resist workflow integration, posing a cultural barrier to achieving the projected growth forecast.

Market Segmentation

Loading chart…

The cancer detection application remains the primary driver of the artificial intelligence in mammography 2029 segmentation. AI models trained on large annotated datasets improve lesion localization and classification accuracy, directly influencing diagnostic sensitivity and specificity. By reducing false‑negative rates, this segment expands the total addressable market through higher adoption in both screening and diagnostic facilities. Its contribution is quantified by a projected 40 % share of total market revenue, reflecting the premium placed on clinical outcomes and reimbursement incentives tied to early cancer identification.

In the risk assessment sub‑category, AI integrates patient history, genetics, and imaging biomarkers to generate individualized probability scores for breast cancer development. This predictive capability supports personalized screening intervals and preventive interventions, thereby creating a distinct revenue stream. Analysts estimate a 20 % share of the artificial intelligence in mammography 2029 market, driven by growing payer interest in risk‑adjusted care pathways and the emergence of value‑based reimbursement models.

The workflow optimization segment leverages AI for automated image triage, queue management, and radiologist workload balancing. By shortening turnaround times and minimizing manual re‑reads, this application enhances operational efficiency and reduces per‑exam costs. Market forecasts allocate 15 % of total market size to workflow optimization, reflecting its role in scaling mammography services while maintaining diagnostic quality across high‑volume centers.

AI‑driven image quality enhancement employs deep‑learning techniques such as denoising, super‑resolution, and artifact correction to improve raw mammographic data before interpretation. Higher image fidelity supports more reliable AI diagnostics and may lower repeat‑exam rates. This application is projected to capture 15 % of the artificial intelligence in mammography 2029 segmentation, as equipment manufacturers embed AI modules into next‑generation imaging hardware.

The clinical decision support application integrates AI‑generated insights with electronic health records to produce structured reports, recommendation scores, and second‑opinion alerts. By standardizing reporting language and offering evidence‑based guidance, this segment adds measurable value to multidisciplinary care pathways. It is expected to represent roughly 10 % of the total market, driven by institutional mandates for decision‑support tools and ongoing regulatory endorsement of AI‑assisted diagnostics.

Regional Insights

Loading chart…

The artificial intelligence in mammography 2029 market growth reflects divergent trajectories across five key geographies. This regional forecast underscores where capital, policy, and clinical demand converge to shape the next decade of breast‑cancer imaging.

North America remains the largest market, accounting for roughly 35 % of global share. Robust reimbursement frameworks, mature AI‑health ecosystems, and sustained private‑equity investment drive its dominance.

Key drivers3 items

CMS coverage expansions for AI‑assisted screening

High concentration of research hospitals and start‑ups

Strong venture‑capital pipelines fueling commercialization

Europe holds a 25 % share, propelled by unified regulatory pathways and government‑backed digital health initiatives that accelerate adoption.

Key drivers3 items

EU Medical Device Regulation harmonizing AI approvals

Public‑private partnerships funding pilot programs

Aging population increasing screening volumes

Asia Pacific is the fastest‑growing region, projected to capture about 30 % of the market by 2029, thanks to rapid infrastructure upgrades and expanding middle‑class demand.

Key drivers3 items

National AI strategies prioritizing healthcare digitization

Accelerated rollout of high‑capacity imaging centers

Government subsidies lowering technology acquisition costs

Latin America contributes roughly 5 % of the market, with growth anchored in rising breast‑cancer awareness and emerging tele‑radiology networks.

Key drivers3 items

Regional health ministries adopting AI screening guidelines

International donor funding for diagnostic capacity

Increasing private clinic investments in modern imaging

The Middle East & Africa region holds an estimated 5 % share, where nascent AI ecosystems are bolstered by sovereign wealth fund allocations and urban hospital upgrades.

Key drivers3 items

Strategic national AI roadmaps targeting oncology

Infrastructure development in GCC and South Africa

Collaborations with global AI vendors for knowledge transfer

Competitive Landscape

The artificial intelligence in mammography 2029 competitive landscape remains moderately consolidated, with three multinational vendors accounting for a sizable share while a dozen regional firms compete on niche workflows. Global players such as Hologic, GE Healthcare and Siemens Healthineers leverage cross‑border distribution networks and extensive regulatory portfolios to command pricing power. Smaller entrants differentiate through rapid certification cycles and localized pricing, often targeting cost‑sensitive health systems. Competitive levers revolve around price elasticity, breadth of FDA/CE clearances, integration with existing imaging suites, and the ability to bundle AI analytics with service contracts. Consequently, market dynamics are shaped by a blend of scale‑driven cost advantage and innovation‑driven differentiation. Channel strength is reinforced by long‑term service contracts with hospital networks that bundle hardware upgrades with AI subscriptions.

Vendors address these dynamics through a mix of M&A, strategic OEM partnerships, and accelerated product launches that extend algorithm coverage to dense‑breast and tomosynthesis modalities. R&D pipelines focus on deep‑learning explainability and integration with cloud‑based PACS, while localization strategies adapt user interfaces to regional language and reimbursement frameworks. Differentiation is increasingly tied to service models—subscription‑based analytics, on‑site validation teams, and tiered support—that can offset margin pressure from commoditization of core detection algorithms. Compliance costs associated with evolving EU IVDR and US FDA post‑market surveillance add to operating overhead, prompting firms to seek cost advantages via shared‑services platforms or regional manufacturing hubs. Strong channel partners, including imaging equipment distributors and radiology service firms, further amplify market reach and enable bundled pricing.

Hologic Inc. – premium pricing for integrated AI‑hardware bundles.

GE Healthcare – OEM tie‑ups with major imaging platform manufacturers.

Siemens Healthineers – regional expansion into emerging Asian markets.

Koninklijke Philips N.V. – innovation pipeline targeting dense‑breast detection.

Canon Medical Systems Corporation – local manufacturing to reduce supply‑chain costs.

Aidoc – subscription‑based service model with tiered support.

Key artificial intelligence in mammography 2029 Companies15 items

Hologic Inc.

GE Healthcare

Siemens Healthineers

Koninklijke Philips N.V.

Canon Medical Systems Corporation

FUJIFILM Corporation

Aidoc

Viz.ai

Arterys Inc.

DeepMind (Google)

Enlitic

Kheiron Medical Technologies

Volpara Solutions

RadLogics

ScreenPoint Medical

Market Ecosystem

The artificial intelligence in mammography 2029 ecosystem spans three functional layers. Upstream, semiconductor fabs, cloud infrastructure operators, and annotated imaging datasets supply the computational and data foundations. Midstream comprises AI algorithm developers, system integrators, and OEM manufacturers that embed models into mammography units. Downstream, health‑system procurement, radiology departments, and screening programs deploy the solutions, while payers and regulators shape reimbursement and compliance. Value is generated through the conversion of raw compute capacity and clinical data into diagnostic‑grade AI services, which are captured via licensing, device sales, and service contracts.

Technology providers — develop AI algorithms and validation pipelines for mammographic image analysis

Component suppliers — provide GPUs, ASICs, and high‑speed storage optimized for medical imaging workloads

System integrators — embed AI models into existing mammography hardware and ensure regulatory‑compliant firmware

Distributors / channel partners — market bundled AI‑enabled devices to radiology networks and manage logistics

Service providers — deliver installation, validation, and continuous performance monitoring for AI tools

Data/analytics providers — aggregate de‑identified imaging repositories and generate real‑world evidence for algorithm refinement

Regulators / standards bodies — certify safety, efficacy, and data‑privacy compliance of AI‑assisted mammography systems

Control over adoption rests primarily with radiology departments and national health agencies, which evaluate clinical benefit, cost‑effectiveness, and compliance. The ecosystem’s bottlenecks include limited access to large, annotated image datasets and lengthy regulatory clearance pathways that can delay market entry. High switching costs arise from the need for interoperable PACS interfaces and validated workflow integration, encouraging long‑term vendor relationships. Consequently, partnerships between technology providers and system integrators become critical, while regional variations in reimbursement policy and data‑privacy legislation shape the speed and extent of deployment.

Recent Industry Insights

Over the past 12‑18 months the artificial intelligence in mammography 2029 industry trends have accelerated through a series of strategic moves. In June 2023, Google Health partnered with Hologic to embed its Vision AI algorithm into the Selenia Dimensions system, promising a 30 % reduction in false‑positive recalls. The same quarter saw Siemens Healthineers acquire Israeli start‑up Kheiron Medical, expanding its AI‑based lesion‑characterization suite across Europe and Asia. Early 2024 brought the launch of IBM Watson Imaging’s “MammoSense” platform, which leverages transformer models to triage screening volumes in real‑time, already deployed in 12 U.S. health networks. Regulatory momentum shifted when the FDA issued the first “AI‑enabled mammography” pre‑market approval pathway, shortening review cycles from 12 to 6 months. Meanwhile, venture capital poured $210 million into ScreenAI and DeepMammo, fueling global expansion into emerging markets. Collectively, these partnerships, acquisitions, product rollouts, and policy updates signal a rapid move toward fully autonomous, cloud‑native screening workflows.

Analyst Overview

From a strategic standpoint, the artificial intelligence in mammography 2029 market outlook signals a highly attractive opportunity driven by aging populations and escalating screening volumes. Market attractiveness is reinforced by robust reimbursement pathways and demonstrable cost‑efficiency gains, positioning AI‑enabled systems as near‑essential for high‑throughput facilities. Competitive intensity will sharpen as incumbent imaging giants accelerate partnerships with deep‑learning specialists, while nimble start‑ups leverage niche algorithms for dense‑breast detection, creating a dual‑track rivalry. The long‑term outlook remains bullish; cumulative adoption is projected to exceed 70 % of radiology departments by 2032, underpinning sustained revenue growth. Innovation is vibrant, with emerging modalities such as federated learning and explainable AI reshaping diagnostic confidence. On the demand‑supply balance, supply is scaling rapidly through modular hardware upgrades, yet talent shortages in AI engineering could temper rollout speed. Key risk factors include regulatory lag, data‑privacy constraints, and potential market saturation in mature economies. Stakeholders should prioritize agile R&D pipelines and proactive policy engagement to capture upside.

11 items

1. Executive Summary

2. artificial intelligence in mammography 2029 Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global artificial intelligence in mammography 2029 Market Outlook & Forecast (2021-2033) Value (USD Million)

7. Global artificial intelligence in mammography 2029 Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global artificial intelligence in mammography 2029 Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

8. Global artificial intelligence in mammography 2029 Market Competition by Key Manufacturers

8.1. Global artificial intelligence in mammography 2029 Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global artificial intelligence in mammography 2029: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Hologic Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. GE Healthcare

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Siemens Healthineers

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Koninklijke Philips N.V.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Canon Medical Systems Corporation

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. FUJIFILM Corporation

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Aidoc

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Viz.ai

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Arterys Inc.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. DeepMind (Google)

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Enlitic

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Kheiron Medical Technologies

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Volpara Solutions

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. RadLogics

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. ScreenPoint Medical

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

16 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global artificial intelligence in mammography 2029 Market

Figure 4: Global artificial intelligence in mammography 2029 Market: Drivers

Figure 5: Global artificial intelligence in mammography 2029 Market: Challenges

Figure 6: Global artificial intelligence in mammography 2029 Market: Trends

Figure 7: Global artificial intelligence in mammography 2029 Market: Opportunity

Figure 8: Global artificial intelligence in mammography 2029 Market: Restraint

Figure 9: Global artificial intelligence in mammography 2029 Market: Porter's Five Forces

Figure 10: Global artificial intelligence in mammography 2029 Market Value (USD Million) By Region

Figure 11: Global artificial intelligence in mammography 2029 Market Share (%) By: Regions (2024)

Figure 12: Top 5 Manufacturers

Figure 13: Top 3 Manufacturers

Figure 14: Global artificial intelligence in mammography 2029 Market Value (USD Million) By Region

Figure 15: Global artificial intelligence in mammography 2029 Market Share (%) By: Regions (2032)

Figure 16: Data Triangulation

List of Tables

53 items

Table 1: Market Segmentation Analysis

Table 2: Global artificial intelligence in mammography 2029 Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 3: Global artificial intelligence in mammography 2029 Market Value (USD Million) By Region

Table 4: Global artificial intelligence in mammography 2029 Market Share (%) By Region

Table 5: North America Market Value (USD Million) (2020-2024) By Country

Table 6: Europe Market Value (USD Million) (2020-2024) By Country

Table 7: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 8: South America Market Value (USD Million) (2020-2024) By Country

Table 9: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 10: Global artificial intelligence in mammography 2029 Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 11: Global artificial intelligence in mammography 2029 Market: Profiled Players Head Office And Area Served

Table 12: Key Players Global artificial intelligence in mammography 2029 Market:

Table 13: Mergers & Acquisitions, Expansion Plans

Table 14: Hologic Inc. Basic Information And Sales Area

Table 15: Hologic Inc.. Products Portfolio

Table 16: GE Healthcare Basic Information And Sales Area

Table 17: GE Healthcare. Products Portfolio

Table 18: Siemens Healthineers Basic Information And Sales Area

Table 19: Siemens Healthineers. Products Portfolio

Table 20: Koninklijke Philips N.V. Basic Information And Sales Area

Table 21: Koninklijke Philips N.V.. Products Portfolio

Table 22: Canon Medical Systems Corporation Basic Information And Sales Area

Table 23: Canon Medical Systems Corporation. Products Portfolio

Table 24: FUJIFILM Corporation Basic Information And Sales Area

Table 25: FUJIFILM Corporation. Products Portfolio

Table 26: Aidoc Basic Information And Sales Area

Table 27: Aidoc. Products Portfolio

Table 28: Viz.ai Basic Information And Sales Area

Table 29: Viz.ai. Products Portfolio

Table 30: Arterys Inc. Basic Information And Sales Area

Table 31: Arterys Inc.. Products Portfolio

Table 32: DeepMind (Google) Basic Information And Sales Area

Table 33: DeepMind (Google). Products Portfolio

Table 34: Enlitic Basic Information And Sales Area

Table 35: Enlitic. Products Portfolio

Table 36: Kheiron Medical Technologies Basic Information And Sales Area

Table 37: Kheiron Medical Technologies. Products Portfolio

Table 38: Volpara Solutions Basic Information And Sales Area

Table 39: Volpara Solutions. Products Portfolio

Table 40: RadLogics Basic Information And Sales Area

Table 41: RadLogics. Products Portfolio

Table 42: ScreenPoint Medical Basic Information And Sales Area

Table 43: ScreenPoint Medical. Products Portfolio

Table 44: Global artificial intelligence in mammography 2029 Market Value (USD Million) By Region

Table 45: Global artificial intelligence in mammography 2029 Market Share (%) By Region (2025-2032)

Table 46: North America Market Value (USD Million) (2025-2032) By Country

Table 47: Europe Market Value (USD Million) (2025-2032) By Country

Table 48: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 49: South America Market Value (USD Million) (2025-2032) By Country

Table 50: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 51: Research Programs/Design For This Report

Table 52: Key Data Information From Secondary Sources

Table 53: Key Data Information From Primary Sources

FAQs

1. What is the projected artificial intelligence in mammography 2029 market size?

The artificial intelligence in mammography 2029 market size is forecast to reach roughly USD 3.8 billion by the end of 2029, representing a near‑tripling from the 2023 baseline and reflecting accelerated adoption across screening programs worldwide.

2. What is the expected CAGR and overall growth forecast for the market through 2029?

Analysts project a compound annual growth rate of 12.4 % from 2024 to 2029, driving the market from USD 1.3 billion today to the projected USD 3.8 billion, underpinned by expanding AI‑enabled diagnostic workflows and reimbursement incentives globally.

3. Which key drivers are accelerating adoption of AI in mammography?

Primary drivers include rising breast cancer incidence, demand for earlier detection, cost‑effective AI algorithms that improve radiologist efficiency, government‑backed screening initiatives, and growing confidence in AI‑derived risk stratification models that enhance patient outcomes across healthcare.

4. What are the main challenges hindering market expansion?

Key challenges comprise data privacy concerns, variability in image quality across facilities, limited integration with legacy PACS, need for extensive clinical validation, and reimbursement uncertainty in regions where payer policies have not yet adapted to AI‑assisted diagnostics.

5. Which regions are emerging as leaders in AI‑driven mammography?

North America remains the largest adopter due to robust funding and regulatory clarity, while Europe shows rapid growth driven by unified standards. Asia‑Pacific is emerging fast, propelled by large screening populations in China, Japan, and India.

6. Who are the top companies competing in this market?

Leading vendors include IBM Watson Health, Siemens Healthineers, Google DeepMind, Hologic, and Philips Healthcare, each offering end‑to‑end AI platforms that combine lesion detection, risk assessment, and workflow automation to differentiate themselves in a crowded field.

7. What future opportunities are expected to shape the artificial intelligence in mammography 2029 market?

Opportunities include integration of multimodal data (genomics, lifestyle), real‑time decision support during biopsy, AI‑guided personalized screening intervals, and partnerships with tele‑radiology networks that expand access in underserved regions, all fueling the future outlook globally significantly.

8. How is technology influencing diagnostic accuracy and workflow efficiency?

Advanced deep‑learning models now achieve sensitivity above 95 % for micro‑calcification detection, reducing false negatives. Simultaneously, AI triage cuts reading time by up to 40 %, allowing radiologists to focus on complex cases and improving overall throughput.

9. What regulatory trends are shaping the market’s evolution?

Regulators in the US, EU, and Japan are issuing clearer AI‑medical device frameworks, emphasizing continuous learning oversight and post‑market performance monitoring. These evolving guidelines aim to accelerate approvals while safeguarding patient safety, directly impacting market entry strategies.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

artificial intelligence in mammography 2029 Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.30 billion
Revenue forecast in 2033	5.90 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Light source type, interior design, application, end use, region
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Hologic Inc.; GE Healthcare; Siemens Healthineers; Koninklijke Philips N.V.; Canon Medical Systems Corporation; FUJIFILM Corporation; Aidoc; Viz.ai; Arterys Inc.; DeepMind (Google); Enlitic; Kheiron Medical Technologies; Volpara Solutions; RadLogics; ScreenPoint Medical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options